Cefadroxil in the management of facial cellulitis of odontogenic origin.
The objectives of this prospective single-blind trial were to compare the efficacy and safety of cefadroxil, 1 gm/day, and cephalexin, 250 mg four times a day, in the treatment of facial cellulitis of odontogenic origin. One hundred sixteen patients were screened for sensitivity to the assigned antibiotic and then randomly assigned treatment groups. Fifty-eight (100%) of the cefadroxil-treated patients and 57 (98%) of the cephalexin-treated patients were considered cured. Adverse reactions were noted in only two cefadroxil-treated patients and one cephalexin-treated patient. One patient from each group discontinued therapy prematurely; the patient who discontinued cephalexin was the only treatment failure in this study. This study found that cefadroxil administered once a day was therapeutically equivalent to cephalexin given four times a day.
Hanna
C B
CB
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002434:Cefadroxil / Q000008:administration & dosage / Q000627:therapeutic use*; D002481:Cellulitis / Q000188:drug therapy* / Q000209:etiology; D002506:Cephalexin / Q000008:administration & dosage / Q000627:therapeutic use*; D004322:Drainage; D005145:Face; D005260:Female; D005491:Focal Infection, Dental / Q000150:complications* / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016037:Single-Blind Method
D002434:Cefadroxil; D002506:Cephalexin